Robert Bohrer is a Professor at the California Western School of Law. He practiced with the Chicago law firm of Bell, Boyd & Lloyd before returning to academia. Although he has written about such varied topics as the constitutionality of I.Q. testing in the public schools, congressional control of affirmative action, and the risks of toxic substances, since 1984 he has focused primarily on the legal issues raised by developments in biotechnology and pharmaceutical policy.


Professor Bohrer is a member of the executive board of the Biolaw Section of the AALS and previously served on the Council of the ABA Section of Science and Technology. Bohrer was executive editor of Biotechnology Law Report from 1999 to 2011. He previously served as director of Biotechnology Programs at the University of California at San Diego’s Center for Molecular Genetics and and on the board of directors of the La Jolla Institute for Molecular Medicine. Bohrer was the only law professor to serve on the board of directors of the Biotechnology Institute of the U.S. Patent and Trademark Office. While in law school at Illinois, he was a member of Law Review and a teaching assistant in the College of Commerce.


Recent Posts by Robert Bohrer

A Better Balance Between Accelerated Access And High-Priced New Drugs: A New Conditional Approval Option

A new form of “conditional approval” could accelerate the approval of new drugs and, at the same time, take at least a small step towards reducing the costs of potentially life-saving drugs.

The Need For Publicly Funded Trials To Get Unbiased Comparative Effectiveness Data

Comparative effectiveness research was one of the hotly debated components of the Affordable Care Act. The pharmaceutical industry is marketing driven, with pharmaceutical companies spending more on marketing than they do on research and development. The need for a marketing edge can also drive...